Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 1, 2015, Pages 97-104

  Zhao, Ke ^a   Lou, Rui ^a   Huang, Fen ^a   Peng, Yanwen ^b   Jiang, Zujun ^c   Huang, Ke ^b   Wu, Xiuli ^d   Zhang, Yu ^a   Fan, Zhiping ^a   Zhou, Hongsheng ^a   Liu, Can ^a   Xiao, Yang ^c   Sun, Jing ^a   Li, Yangqiu ^d   Xiang, Peng ^b   Liu, Qifa ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^d MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

Graft versus host disease; Hematopoietic stem cell transplantation; Immunomodulation; Mesenchymal stromal cell

Indexed keywords

BASILIXIMAB; BUSULFAN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYTARABINE; DNA; FLUDARABINE; MEPREDNISONE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; T LYMPHOCYTE RECEPTOR; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW; BRAIN HEMORRHAGE; CANCER RECURRENCE; CD3 CD4 T CELL; CD3 CD8 T CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DONOR; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LUNG HEMORRHAGE; LYMPHOPROLIFERATIVE DISEASE; MALE; MESENCHYMAL STROMA CELL; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; OPEN STUDY; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE; RISK; T LYMPHOCYTE; TREATMENT RESPONSE; ACUTE DISEASE; ALLOTRANSPLANTATION; CLINICAL TRIAL; CYTOLOGY; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; UNRELATED DONORS;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 84925606379     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.09.030     Document Type: Article

References (52)

1. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
2. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96:2062-2068.
3. Bacigalupo A. Management of acute graft-versus-host disease. Br J Haematol 2007, 137:87-98.
4. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002, 8:387-394.
5. von Bonin M., Stolzel F., Goedecke A., et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009, 43:245-251.
6. Deeg H.J. How I treat refractory acute GVHD. Blood 2007, 109:4119-4126.
7. Mosna F., Sensebe L., Krampera M. Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide. Stem Cells Dev 2010, 19:1449-1470.
8. Cavarretta I.T., Altanerova V., Matuskova M., et al. Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther 2010, 18:223-231.
9. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008, 8:726-736.
10. Le Blanc K., Ringden O. Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol 2006, 18:586-591.
11. Wang S., Qu X., Zhao R.C. Clinical applications of mesenchymal stem cells. JHematol Oncol 2012, 5:19.
12. Muller I., Kordowich S., Holzwarth C., et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 2008, 40:25-32.
13. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
14. Weng J.Y., Du X., Geng S.X., et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010, 45:1732-1740.
15. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
16. Perez-Simon J.A., Lopez-Villar O., Andreu E.J., et al. Mesenchymal stem cells expanded invitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica 2011, 96:1072-1076.
17. Prasad V.K., Lucas K.G., Kleiner G.I., et al. Efficacy and safety of exvivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011, 17:534-541.
18. Kebriaei P., Isola L., Bahceci E., et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:804-811.
19. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
20. Koreth J., Antin J.H. Current and future approaches for control of graft-versus-host disease. Expert Rev Hematol 2008, 1:111.
21. Liu X., Wu M., Peng Y., et al. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Cell Transplant 2014, 23:1087-1098.
22. Xuan L., Huang F., Fan Z., et al. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. JHematol Oncol 2012, 5:46.
23. Wu X., Zhu K., Du X., et al. Frequency analysis of TRBV subfamily sjTRECs to characterize T-cell reconstitution in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. JHematol Oncol 2011, 4:19-27.
24. Westin J.R., Saliba R.M., De Lima M., et al. Steroid-refractory acute GVHD: Predictors and outcomes. Adv Hematol 2011, 2011:601953.
25. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
26. Styczynski J., Reusser P., Einsele H., et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009, 43:757-770.
27. Liu Q.F., Fan Z.P., Zhang Y., et al. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Biol Blood Marrow Transplant 2009, 15:1376-1385.
28. Cheson B.D. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am 2007, 21:841-854.
29. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
30. Trotti A., Colevas A.D., Setser A., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
31. Galipeau J. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?. Cytotherapy 2013, 15:2-8.
32. Zhao S., Wehner R., Bornhauser M., et al. Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells Dev 2010, 19:607-614.
33. Ringden O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
34. Herrmann R., Sturm M., Shaw K., et al. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study. Int J Hematol 2012, 95:182-188.
35. Martin P.J., Uberti J.P., Soiffer R.J., et al. Prochymal improves response rates in patients with steroid-refractory acute graft-versus-host disease involving the liver and gut: results of a randomized, placebo-controlled, multicentre phase III trial in GvHD. Biol Blood Marrow Transplant 2010, 16:S169-S172.
36. Bernardo M.E., Fibbe W.E. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 2013, 13:392-402.
37. Joo S.Y., Cho K.A., Jung Y.J., et al. Bioimaging for the monitoring of the invivo distribution of infused mesenchymal stem cells in a mouse model of the graft-versus-host reaction. Cell Biol Int 2011, 35:417-421.
38. Keating A. How do mesenchymal stromal cells suppress T cells?. Cell Stem Cell 2008, 2:106-108.
39. Jitschin R., Mougiakakos D., Von Bahr L., et al. Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation. Stem Cells 2013, 31:1715-1725.
40. Peng Y., Chen X., Liu Q., et al. Alteration of naive and memory B-cell subset in chronic graft-versus-host disease patients after treatment with mesenchymal stromal cells. Stem Cells Transl Med 2014, 3:1023-1031.
41. Peng Y., Chen X., Liu Q., et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10. Leukemia 2014, [Epub ahead of print]. 10.1038/leu.2014.225.
42. Poulin J.F., Sylvestre M., Champagne P., et al. Evidence for adequate thymic function but impaired naive T-cell survival following allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease. Blood 2003, 102:4600-4607.
43. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10:490-500.
44. Itoi M., Tsukamoto N., Yoshida H., Amagai T. Mesenchymal cells are required for functional development of thymic epithelial cells. Int Immunol 2007, 19:953-964.
45. Alpdogan O., van den Brink M.R. Immune tolerance and transplantation. Semin Oncol 2012, 39:629-642.
46. Krenger W., Blazar B.R., Hollander G.A. Thymic T-cell development in allogeneic stem cell transplantation. Blood 2011, 117:6768-6776.
47. Jenkinson W.E., Jenkinson E.J., Anderson G. Differential requirement for mesenchyme in the proliferation and maturation of thymic epithelial progenitors. JExp Med 2003, 198:325-332.
48. Liu K., Chen Y., Zeng Y., et al. Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study. Stem Cells Dev 2011, 20:1679-1685.
49. Karlsson H., Samarasinghe S., Ball L.M., et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 2008, 112:532-541.
50. von Bahr L., Sundberg B., Lonnies L., et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2012, 18:557-564.
51. Auletta J.J., Deans R.J., Bartholomew A.M. Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. Blood 2012, 119:1801-1809.
52. Cassatella M.A., Mosna F., Micheletti A., et al. Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. Stem Cells 2011, 29:1001-1011.